To Get Full Access :
Ekterly is the first and only oral, on-demand therapy for hereditary angioedema (HAE) attacks in patients aged 12 and older. It works by inhibiting plasma kallikrein, preventing excessive bradykinin production to reduce swelling rapidly. Approved in the U.S. and U.K. in 2025, Ekterly offers fast relief, convenient oral dosing, and a major advance over injectable treatments, giving patients greater independence and control during acute HAE episodes.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
